BYOOVIZ, approved by the FDA in September 2021 as the first ophthalmology biosimilar in the US, has been commercially available since June 2022 Samsung Bioepis
Existing Klarity-C Patients to Have Access to VEVYE for $59 Per Bottle Harrow, a leading North American eyecare pharmaceutical company, announced an expansion of its VEVYE Access
Groundbreaking Access Program to Reduce Patient Barriers to Dry Eye Disease Therapy Harrow, a leading North American eyecare pharmaceutical company, today introduced VEVYE Access for All, a
Fuel up with free Health Tech Insights
